ArticleMultiple sclerosis journal - experimental, translational and clinical
Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab.
Mark Gudesblatt et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.